Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Citius Pharmaceuticals, Inc.

Get SEC filing alerts via email and in your feed for Citius Pharmaceuticals, Inc.

CTXR

Citius Pharmaceuticals, Inc.

About Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals develops proprietary critical care and dermatological products, including Mino-Lok for catheter infection salvage, Halo-Lido for hemorrhoid relief, and NoveCite stem cell therapy for ARDS. The company focuses on reformulations of approved drugs with strong safety data, targeting large, underserved markets. It leverages regulatory exclusivity, innovative applications, and strategic licensing to provide effective, lower-risk therapeutic solutions.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Citius Pharmaceuticals, Inc.

1
1
Citius Pharmaceuticals, Inc. Citius Pharmaceuticals Reports $1.67M Revenue in Q2 2026, Faces $28.11M Net Loss

Via official filing (AI summary) | 19 days ago | 0 comments

2
1
Citius Pharmaceuticals, Inc. Citius Pharmaceuticals Reports $3.94 Million Revenue in Q1 FY 2026, Net Loss of $9.39 Million

Via official filing (AI summary) | 4 months ago | 0 comments

3
1
Citius Pharmaceuticals, Inc. Citius Pharmaceuticals Reports $39.7 Million Net Loss for Fiscal Year Ending September 30, 2025

Via official filing (AI summary) | 5 months ago | 0 comments

4
1
Citius Pharmaceuticals, Inc. Citius Pharmaceuticals Reports Q3 2025 Financial Results with $9.2 Million Net Loss

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Citius Pharmaceuticals, Inc. Citius Pharmaceuticals Reports $11.5 Million Net Loss and Zero Revenue for Quarter Ending March 31, 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Citius Pharmaceuticals, Inc. Citius Pharmaceuticals Reports $10.3 Million Net Loss, No Revenue in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments